These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 31578100

  • 21. OnabotulinumtoxinA injection in the treatment of chronic migraine.
    Wang YF.
    Prog Brain Res; 2020; 255():171-206. PubMed ID: 33008506
    [Abstract] [Full Text] [Related]

  • 22. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial.
    Pollard DJ, Brennan A, Dixon S, Waugh N, Elliott J, Heller S, Lee E, Campbell M, Basarir H, White D, REPOSE group.
    BMJ Open; 2018 Apr 07; 8(4):e016766. PubMed ID: 29627802
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
    Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group.
    Cephalalgia; 2010 Jul 07; 30(7):793-803. PubMed ID: 20647170
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C, Stark R, Limberg N, Rodrigues J, Cordato D, Schwartz R, Jukic R.
    J Headache Pain; 2019 Jul 15; 20(1):81. PubMed ID: 31307383
    [Abstract] [Full Text] [Related]

  • 29. Development of onabotulinumtoxinA for chronic migraine.
    Whitcup SM, Turkel CC, DeGryse RE, Brin MF.
    Ann N Y Acad Sci; 2014 Nov 15; 1329():67-80. PubMed ID: 25399521
    [Abstract] [Full Text] [Related]

  • 30. Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine.
    Blumenfeld AM, Aurora SK, Laranjo K, Papapetropoulos S.
    BMC Neurol; 2015 Jul 03; 15():100. PubMed ID: 26133547
    [Abstract] [Full Text] [Related]

  • 31. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data.
    Lanteri-Minet M, Ducros A, Francois C, Olewinska E, Nikodem M, Dupont-Benjamin L.
    Cephalalgia; 2022 Dec 03; 42(14):1543-1564. PubMed ID: 36081276
    [Abstract] [Full Text] [Related]

  • 32. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.
    Health Technol Assess; 2007 Nov 03; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [Abstract] [Full Text] [Related]

  • 33. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld AM.
    J Headache Pain; 2019 Feb 01; 20(1):12. PubMed ID: 30709333
    [Abstract] [Full Text] [Related]

  • 34. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J, Al MJ.
    Pharmacoeconomics; 2017 Dec 01; 35(12):1211-1221. PubMed ID: 28656543
    [Abstract] [Full Text] [Related]

  • 35. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.
    Health Technol Assess; 2006 Mar 01; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [Abstract] [Full Text] [Related]

  • 36. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
    Rothrock JF, Adams AM, Lipton RB, Silberstein SD, Jo E, Zhao X, Blumenfeld AM, FORWARD Study investigative group.
    Headache; 2019 Nov 01; 59(10):1700-1713. PubMed ID: 31559634
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M, Pandor A, Hamilton J, Stevens J, Rowntree C, Martyn-St James M, Rawdin A, Wong R.
    Pharmacoeconomics; 2018 Jul 01; 36(7):759-768. PubMed ID: 29502175
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.